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A sufficient energy supply is essential for life; consequently, multiple mechanisms have evolved to
ensure both energy availability and conservation during fasting and starvation. Two reports in this
issue of Cell Metabolism (Badman et al., 2007; Inagaki et al., 2007) demonstrate that FGF21, a circu-
lating protein produced in the liver in response to the PPARa transcription factor, is a ‘‘missing link’’ in
the biology of fasting, inducing adipose tissue lipolysis, liver ketogenesis, and metabolic adaptation
to the fasting state.Biology of Fasting
The adaptation from the fed to fasted
(total lack of food intake, usually acute)
or starved (chronic undernutrition)
state has been a subject of fascination,
and investigation, for centuries (Cahill,
2006; Keys et al., 1950; see also
Tucker, 2006). In the fed state, glucose
fulfills the body’s acute, immediate en-
ergy needs. The body senses a drop in
glucose concentration at sites such as
the pancreatic islets, brain, and portal
vein. It responds by reducing insulin
secretion from islet b cells and by in-
creasing glucagon secretion from islet
a cells. Another response is sympa-
thetic adrenal stimulation causing in-
creased epinephrine levels; this arm
is of secondary importance but has
a larger role in patients with type 2
diabetes (Cryer et al., 2003).
During fasting, liver glycogen, a
glucose-storage polymer, is initially
mobilized to replenish blood glucose
(glycogenolysis). Major changes in
metabolism occur as the glycogen
supply dwindles. Stored adipose tis-
sue triglycerides are released into the
circulation as glycerol and fatty acids.
The glycerol is converted by the liver
into glucose (gluconeogenesis). The
fatty acids are directly oxidized as an
energy source by some tissues (liver
and muscle); the liver also metabolizes
the fatty acids to b-hydroxybutyrate
and acetoacetate (‘‘ketone bodies’’).
Ketone bodies are released into the
circulation for use by tissues, notably
the brain, which cannot use fatty
acids. The liver also uses ketones for
gluconeogenesis. When fasting is
prolonged, muscle protein breakdownoccurs, sending alanine to the liver as
another substrate for gluconeogenesis
(Cahill, 2006).
The major controllers of energy ho-
meostasis are insulin, glucagon, and
the sympathetic nervous system, but
other regulator hormones play a role
too. Leptin is secreted by adipose
tissue in proportion to adipose triglyc-
eride content (the determinant of how
long the body can survive starvation);
this information on triglyceride levels
controls chronic energy homeostasis
and related events, including, for ex-
ample, the ability to reproduce. Other
physiological signals of energy status
include the gut hormones that com-
municate nutritional status (examples
include ghrelin, cholecystokinin,
pancreatic polypeptide, glucagon-
like peptide-1, polypeptide YY, gas-
trin-releasing peptide, and neurome-
din U). None of these gut hormones,
however, has the dramatic, nonredun-
dant importance of insulin, glucagon,
or leptin, as evidenced by the defi-
ciency phenotypes of the respective
knockout mice. Hypothetical roles
for as yet undiscovered hormones
might include hormones secreted by
the liver reporting its glycogen or
triglyceride content, or by muscle
broadcasting that its glycogen stores
are low or that its lactate production
is high.
Over the past few years, it has
become clear that there is another
source of ‘‘hormonal’’ information on
fuel homeostasis. There are now a
number of examples of the metabolic
fuels themselves serving as hormones
(i.e., as ligands without undergoingCell Metabolfurther metabolism). Metabolic sub-
strate G protein-coupled receptors
include GPR109A for b-hydroxybuty-
rate, GPR91 for succinate, GPR99
for a-ketoglutarate, and GPR41 and
GPR43 for short-chain fatty acids. In-
tracellular transcription factors that
appear to be fuel sensors are HNF4
and PPARs for fatty acids (among
others; see Lazar and Willson, 2007).
FGF21
FGF21 burst into the picture when
Kharitonenkov et al. (2005) showed
that it improved glucose, insulin, and
triglyceride levels in diabetic mice
and that transgenic overexpression re-
sulted in a lean, insulin-sensitive phe-
notype. A follow-up study of 6 weeks’
treatment of diabetic rhesus monkeys
significantly expanded these results:
FGF21 reduced glucose, insulin, and
glucagon levels; improved lipid pro-
files; and slightly reduced body weight
(Kharitonenkov et al., 2007). Of signifi-
cant interest for identifying possible
pharmaceutical targets, no signals
of hypoglycemia or cell proliferation
were detected.
The two papers in this issue
(Badman et al., 2007; Inagaki et al.,
2007) establish FGF21 as a hormone
important in the intermediate time pe-
riod (hours) in the body’s adaptation
to fasting. The papers complement
each other well, with Inagaki et al. con-
centrating on FGF21 excess, showing
that it is sufficient, while Badman
et al. focus on FGF21 deficiency (liver
knockdown), showing that it is nec-
essary, for adaptation to fasting
(Figure 1).ism 5, June 2007 ª2007 Elsevier Inc. 405
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Fuels are shown in black italics, and regulators are shown in red. FGF21 actions on liver are de-
picted as endocrine but could also be paracrine. Fasting is detected by the brain, leading to lipol-
ysis and contributing to other adaptations such as torpor. Fatty acids are released from adipose
tissue, taken up by the liver, and either oxidized or converted to ketones. Ketones released by the
liver are used as fuel by the brain. Activation of PPARa, presumably via activation by fatty acids,
increases transcription of FGF21. FGF21 contributes to ketogenesis in liver, lipolysis in adipose,
and adaptation such as torpor by the brain.Both groups place FGF21 down-
stream of the transcription factor
PPARa (the target of the fibrate class
of triglyceride-lowering drugs), which
has been identified as a key regulator
of the adaptation to fasting (Lefebvre
et al., 2006). They report that fasting
or PPARa agonist treatment increased
liver FGF21 mRNA levels about 25-
fold. PPARa/ mice showed reduced
basal FGF21 mRNA levels with no re-
sponse to PPARa agonist and only
a partial increase in FGF21 mRNA
upon fasting. Inagaki et al. (2007) dem-
onstrate PPAR binding elements in the
FGF21 promoter, suggesting that this
is a direct effect, possibly mediated
by fatty acid binding to PPARa. They
show that in the fed state, FGF21 in-
creases adipose tissue lipolysis and
hepatic ketogenesis, increasing circu-
lating b-hydroxybutyrate and reducing
glucose, insulin, and cholesterol levels
(confirming the findings of Kharitonen-
kov et al., 2005). The effects of FGF21
in the fed statemimic the adaptation to
the fasted state seen in control mice.
PPARa/ mice are known to have
an abnormal response to fasting, in-
cluding defective fatty acid oxidation
and ketogenesis (Kersten et al.,
1999), defects that were partially rem-
edied by FGF21 dosing. FGF21 also406 Cell Metabolism 5, June 2007 ª2007caused adipose lipolysis, providing
fatty acids to the liver for ketogenesis,
and induced torpor, a state character-
ized by physical inactivity and a low
body temperature. Small mammals
normally require a high metabolic rate
in order to maintain body temperature
but use torpor as an adaptive strategy
to conserve energy when food is
scarce.
Badman et al. (2007) identify FGF21
as a liver mRNA induced in mice sub-
jected to fasting, fed a ketogenic diet,
or treated with a PPARa agonist. Cir-
culating FGF21 protein levels in-
creased (about 2-fold) with fasting
and returned to fed levels by 4 hr of
refeeding but were only modestly re-
duced in the PPARa/mice. Interest-
ingly, the elevated FGF21mRNA levels
of the ketogenic diet were not reduced
in the PPARa/ mice, indicating that
induction of FGF21 can also be inde-
pendent of PPARa. Adenovirus knock-
down of liver FGF21 expression in
mice on a ketogenic diet caused fatty
liver, lipemia, and reduced serum
ketones, with reductions in liver RNAs
for fatty acid oxidation and ketogene-
sis genes. The combined observations
that FGF21 regulates adipose (lipoly-
sis), liver (fatty acid oxidation and
ketogenesis), and brain (torpor) estab-Elsevier Inc.lish it as a major endocrine regulator of
the response to fasting.
What Are the Unanswered
Questions?
As with any new hormone, there is
much to learn about FGF21’s biology.
For example: What role does it have
in other ketogenic states, such as the
newborn period, lactation, and preg-
nancy? Are some effects of FGF21 au-
tocrine or paracrine, rather than endo-
crine? Does FGF21 reach the brain
directly, or are its actions there indi-
rect? A fascinating observation is that
some seizure disorders that are un-
responsive to other therapies are
effectively treated by a ketogenic diet
(Freeman et al., 2007). There is no
clear mechanistic understanding for
this success. Presumably FGF21 is
induced in these patients. Might it
also have a role in their treatment?
FGF21 is but one member of a 22-
member family. However, three mem-
bers, FGF21, FGF19 (Fgf15 in the
mouse), and FGF23, constitute a dis-
tinct subfamily and share a number of
attributes atypical for FGFs. The three
appear to be classical endocrine hor-
mones, being made in distinct sites
(FGF21 in liver, FGF19/Fgf15 in intes-
tine, and FGF23 in osteoblast) and act-
ing distantly (FGF19/Fgf15 represses
bile acid synthesis and inhibits gall-
bladder emptying; FGF23 regulates
phosphaturia and vitamin D metabo-
lism). These FGFs bind heparin rela-
tively poorly, presumably facilitating
their endocrine rather than paracrine
actions and their need for Klotho/b-
Klotho receptor accessory proteins
(Goetz et al., 2007).
What receptor (or receptors) is
FGF21 acting through? There are four
FGF receptor genes with tyrosine
kinase activity, with multiple splice
isoforms that affect specificity and
thus receptor function. Additionally,
receptor activity can be dependent
on receptor-associated proteins. A
recent paper shows that b-Klotho,
a transmembrane protein that associ-
ates with FGF receptors 1c and 4, is
required for FGF21 signaling in 3T3-
L1 adipocytes (Ogawa et al., 2007).
This is an exciting development that
should help answer selectivity and
specificity questions.
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diabetes, dyslipidemia, and/or obe-
sity? The favorable diabetes and lipid
phenotypes are encouraging. The
rhesus studies (Kharitonenkov et al.,
2007) suggest that these effects are
not rodent specific (for example, due
to the higher rodent liver PPARa levels
or the importance of active brown adi-
pose tissue). On the safety front, the
lack of detected hypoglycemia or cell
proliferation is important. Thus, this
mechanism seems worthy of further
investigation.
The observations reported in this
issue by Badman et al. (2007) and In-
agaki et al. (2007) identify FGF21 as
an important endocrine hormone
helping control adaptation to the
fasted state. This provides a previ-
ously missing link, downstream of
PPARa, by which the liver communi-
cates with the rest of the body in
regulating the biology of energy ho-
meostasis.Live Longer thro
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DR-induced life-span extension i
The notion that life span is subject to
the action of genes has becomewidely
accepted. Despite the claims of popu-
lar anti-aging pills and creams, dietary
restriction (DR) or calorie restriction is
the only general nongenetic interven-
tion that has been shown to improve
health and increase life span in various
model systems. DR differs from star-
vation and is usually defined as about
30% lower food intake than that of ad
libitum feeding. In addition to DR, life
span can be extended by reduced in-
sulin/IGF-1 signaling (IIS) and reducedACKNOWLEDGMENTS
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